Ascendio

012170 · KOSPI · Communication Services · SMALL CAP

Change of largest shareholder

Following payment for a third-party-allotment rights offering, Ascendio Co., Ltd.'s largest shareholder changed from Kiwi No.1 Partnership (46.30%) to Gyeongnam Pharmaceutical Co., Ltd. and 1 other (70.20%) on August 10, 2026, with the 3,246,683 newly acquired shares subject to a 1-year lock-up.

Ownership change(Change of largest shareholder)· FILED 2026-08-10· RCEPT 20260810800378

What happened

Ascendio / Change of Largest Shareholder / (2026.08.10) Change of Largest Shareholder

Change of Largest Shareholder

1. Details of the change Largest shareholder before change: Kiwi No.1 Partnership Shares held (shares): 1,875,290 Ownership ratio (%): 46.30 Largest shareholder after change: Gyeongnam Pharmaceutical Co., Ltd. and 1 other Shares held (shares): 5,121,973 Ownership ratio (%): 70.20

2. Reason for change Change of largest shareholder due to payment for a third-party allotment rights offering

3. Purpose of acquiring the stake Participation in management Method of financing the acquisition: Contribution in kind of real estate Plan for appointment/dismissal of executives after acquisition: -

4. Date of change: 2026-08-10

5. Date of confirmation of change: 2026-08-10

6. Other matters material to investment decisions - The 3,246,683 shares acquired through the rights offering will be subject to a mandatory 1-year holding period from the listing date. - In "1. Details of the change" above, the "before change" shares held reflect the share count after a reverse stock split from the previously held shares; the "before change" ownership ratio (%) is based on total shares issued before payment for the rights offering (4,050,038 shares), and the "after change" ownership ratio (%) is based on total shares issued after payment for the rights offering (7,296,721 shares). - The financial status of Gyeongnam Pharmaceutical Co., Ltd., the largest shareholder after the change, is as follows (as of 2025.12.31): Total assets: KRW 155,630 million Total liabilities: KRW 47,331 million Total equity: KRW 108,300 million Capital: KRW 7,815 million ※ Related disclosures: 2026-07-07 Decision on rights offering; 2026-07-07 Decision to acquire tangible assets; 2026-07-31 Decision on rights offering; 2026-08-10 Results of rights offering or equity-linked bond issuance (voluntary)

Detailed changes Name (corporation): Relationship; Shares held before change (shares); Ownership ratio before change (%); Shares held after change (shares); Ownership ratio after change (%); Remarks Kiwi No.1 Partnership: Largest shareholder before change; 1,875,290; 46.30; 1,875,290; 25.70; - Gyeongnam Pharmaceutical Co., Ltd.: Largest shareholder after change; -; -; 3,246,683; 44.50; - Kiwi No.1 Partnership: Person related to the largest shareholder after change; 1,875,290; 25.70; 1,875,290; 25.70; -

Filed2026-08-10, Change of largest shareholder
SourceDART rcept 20260810800378 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-08-10 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).